Pfizer's Metsera deal could spark more M&A for pharmas 'tiptoeing into obesity'

Pfizer's up to $7.3 billion acquisition of Metsera earlier this week was the first big pharma purchase of an obesity biotech since Roche’s buyout of Carmot Therapeutics in late 2023. Analysts told Endpoints News they ...